Last reviewed · How we verify

Antibiotics administration

The Central and Eastern European Gynecologic Oncology Group · FDA-approved active Small molecule

Antibiotics kill or inhibit bacterial pathogens by targeting bacterial cell wall synthesis, protein synthesis, or DNA replication.

Antibiotics kill or inhibit bacterial pathogens by targeting bacterial cell wall synthesis, protein synthesis, or DNA replication. Used for Bacterial infections in gynecologic oncology patients, Prophylaxis of infection in immunocompromised cancer patients.

At a glance

Generic nameAntibiotics administration
SponsorThe Central and Eastern European Gynecologic Oncology Group
Drug classAntibiotic (broad class)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Supportive Care in Oncology
PhaseFDA-approved

Mechanism of action

Antibiotics are a broad class of antimicrobial agents used to treat bacterial infections. Different antibiotic classes work through distinct mechanisms: beta-lactams inhibit cell wall synthesis, aminoglycosides and macrolides disrupt protein synthesis, and fluoroquinolones interfere with DNA replication. In gynecologic oncology contexts, antibiotics are typically used as supportive care to prevent or treat infections in immunocompromised cancer patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: